• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

    76.48 +0.36 (+0.47%)
    Streaming Delayed Price Updated: 10:04 AM EDT, Jul 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Bright Minds Biosciences Inc. - common stock

    News headline image
    Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    MarketBeat Week in Review – 10/14 - 10/18
    Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
    Via AB Newswire
    News headline image
    Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences Stock Surges Almost 1,500%
    Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news. 
    Via MarketBeat
    News headline image
    Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
    From Bright Minds Biosciences
    Via GlobeNewswire
    Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
    EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Bright Minds Biosciences Inc. (NASDAQ: DRUG) Leading the Way in Tuesday Trading Based on Percentage Gain
    Via Investor Brand Network
    News headline image
    New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
    A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The... 
    Via PressReach
    Topics Supply Chain
    New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking... 
    Via FinancialNewsMedia
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.